An evaluation of cytotoxicity of the taxane and platinum agents combination treatment in a panel of human ovarian carcinoma cell lines

Gynecologic Oncology

Volumn 98, Issue 1, 2005, Pages 141-145

  Smith, Judith A ^a,b,c   Ngo, Hop ^b   Martin, Miranda C ^a   Wolf, Judith K ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Cancer; Carboplatin; Cisplatin; Docetaxel; Ovarian; Paclitaxel

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; PACLITAXEL; PLATINUM DERIVATIVE; TAXANE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CALCULATION; CANCER CELL CULTURE; CANCER INHIBITION; CELL COUNT; CELL DEATH; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; IC 50; INTERMETHOD COMPARISON; OPTICAL DENSITY; OVARY CARCINOMA; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; OVARIAN NEOPLASMS; PACLITAXEL; TAXOIDS;

EID: 20444448808     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2005.02.006     Document Type: Article

References (23)

1. M.N. Barnes, W.E. Grizzle, C.J. Grubbs, and E.E. Partridge Paradigms for primary prevention of ovarian carcinoma CA Cancer J. Clin. 52 2002 216 225
2. A. Jemal, A. Thomas, T. Murray, and M. Thun 2004 Cancer Statistics CA Cancer J. Clin. 54 1 2004 8 29
3. W.P. McGuire, and M. Markman Primary ovarian cancer chemotherapy: current standards of care Br. J. Cancer 89 Suppl 3 2003 S3 S8
4. M.F. de Jonge, R.A.A. Mathôt, S.M. van Dam, J.H. Beijnen, and S. Rodenhuis Extremely high exposures in an obese patient receiving high-dose clcyophosphamide, thiotepa, and carboplatin Cancer Chemother. Pharmacol. 50 2002 251 255
5. A.D.R. Hitema, M. Spaander, R.A.A. Mathôt, M.M. Tibben, M.J. Holtkamp, and J.H. Beijen Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin Ann. Oncol. 13 2002 374 384
6. M.A. Bookman, B.E. Greer, and R.F. Ozols Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG158) and an update on GOG 182-ICON5 Int. J. Gynecol. Cancer 13 2003 735 740
7. R.F. Ozols, B.N. Bundy, and B.E. Greer Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecology Oncology Group Study J. Clin. Oncol. 21 2003 3194 3200
8. A. du Bois, H.J. Luck, and W. Meir A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer JNCI 95 7 2003 1130 1320
9. J. Pfisterer, A. du Bois, U. Wagner, J. Quaas, J.U. Blohmer, and D. Wallwiener Docetaxel and carboplatin as first-line chemotherapy in patients with advanced gynecological tumors. A phase I/II trial of the Arbeitsgemeinschaft Gynakogische Onkologie (AGO-OVAR) Ovarian Cancer Study Group Gynecol. Oncol. 92 2004 949 956
10. P.A. Vasey, J. Paul, and A. Birt A phase III comparison of paclitaxel/carboplatin and docetaxel/carboplatin as first-line chemotherapy for stage IC-IV ovarian cancer Proc. Am. Soc. Clin. Oncol. 20 2001 202a
11. P. Kornblith, A. Wells, M.J. Gabrin, J. Piwowar, A. Chattopadhyay, and L.D. George In vitro responses of ovarian cancer to platinums and taxanes Anticancer Res. 23 1B 2003 543 548
12. L.R. Kelland, and G. Abel Comparative in vitro cytotoxicity of taxol and taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell Cancer Chemother. Pharmacol. 30 6 1992 444 450
13. P. Engblom, V. Rantanen, J. Kulmala, H. Helenius, and S. Grenman Additive and supra-additive cytotoxicity of cisplatin-taxane combinations in ovarian carcinoma cell lines Br. J. Cancer 79 2 1999 286 292
14. P. Engblom, V. Rantanen, J. Kulmala, and S. Grenman Carboplatin- paclitaxel and carboplatin-docetaxel-induced cytotoxic effect in epithelial ovarian carcinoma in vitro Cancer 86 10 1999 2066 2073
15. D.S. Alberts, P.T. Fanta, K.L. Running, L.P. Adair, D.J. Garcia, and R. Liu-Steves In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human ovarian cancers Cancer Chemother. Pharmacol. 39 1997 493 497
16. P. Engblom, V. Rantanen, J. Kulmala, and S. Grenman Paclitaxel and cisplatin sensitivity of ovarian carcinoma cell lines tested with the 96-well plate clonogenic assay Anticancer Res. 16 1996 1743 1748
17. C.M. Garner, L.M. Hubbold, and P.R. Chakrabori In vitro testing of platinum-based drugs on a panel of human tumour cell lines Br. J. Biol. Med. Sci. 59 1 2002 15 19
18. J.P. Neijt, S.A. Engelhlom, and M.K. Tuxen Exploratory phase II study of paclitaxel and cisplatin verses paclitaxel and carboplatin in advanced ovarian cancer J. Clin. Oncol. 18 2000 3084 3092
19. M.J. Piccart, K. Bertelsen, and K. James Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results J. Natl. Cancer Inst. 92 9 2000 (May 3) 699 708
20. International Collaborative Ovarian Neoplasm Group Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomized trial Lancet 360 9332 2002 (Aug 17) 505 515
21. P.A. Vasey, J. Paul, and A. Birt Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer J. Clin. Oncol. 17 1999 2069 2080
22. M.C. Bissery, G. Nohynek, and F. Lavelle Docetaxel: review of preclinical and clinical experience Anticancer Drugs 6 1995 339 368
23. A. Covens, M. Carey, and P. Bryson Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with I.I. stage, III, or IV epithelial ovarian cancer Gynecol. Oncol. 85 2002 71 80